KASID
Search
- Page Path
- HOME > Search
Original Articles
- IBD
- Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease
- Paulo Gustavo Kotze, Daniela Oliveira Magro, Barbara Saab, Mansur Paulo Saab, Lilian Vital Pinheiro, Marcia Olandoski, Maria de Lourdes Setsuko Ayrizono, Carlos Augusto Real Martinez, Claudio Saddy Rodrigues Coy
- Intest Res 2018;16(1):62-68. Published online January 18, 2018
- DOI: https://doi.org/10.5217/ir.2018.16.1.62
-
Abstract
PDF
PubReader
ePub <b>Background/Aims</b><br/> The use of anti-tumor necrosis factor (anti-TNF) agents seems to reduce surgical rates and delay surgical procedures in prospective trials and population-based studies in the management of Crohn's disease (CD). This study aimed to identify whether preoperative anti-TNF agents influence the time from diagnosis to surgery.
Methods An observational retrospective cohort study was conducted on patients with CD submitted to intestinal resections due to complications or medical therapy failure in a period of 7 years. The patients were allocated into 2 groups according to their previous exposure to anti-TNF agents in the preoperative period. Epidemiological aspects regarding age at diagnosis, smoking, perianal disease, and preoperative conventional therapy were considered. A Kaplan-Meier survival analysis was used to outline possible differences between the groups regarding the time to surgery.
Results A total of 123 patients were included (71 and 52 with and without previous exposure to biologics, respectively). The overall time to surgery was 108±6.9 months (maximum, 276 months). The survival estimation revealed no difference in the mean time to intestinal resection between the groups (99.78±10.62 months in the patients without and 114.01±9.07 months in those with previous anti-TNF use) (log-rank
P =0.35). There was no significant difference in the time to surgery regarding perianal CD (P =0.49), smoking (P =0.63), preoperative azathioprine (P =0.073) and steroid use (P =0.58).Conclusions The time from diagnosis to surgery was not influenced by the preoperative use of anti-TNF therapy in this cohort of patients.
-
Citations
Citations to this article as recorded by
- Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America
Domingo Balderramo, Abel Botelho Quaresma, Pablo A Olivera, Mariane Christina Savio, Maria Paz Gimenez Villamil, Remo Panaccione, Siew C Ng, Gilaad G Kaplan, Paulo Gustavo Kotze
The Lancet Gastroenterology & Hepatology.2024; 9(3): 263. CrossRef - Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Intestinal Research.2022; 20(1): 72. CrossRef - Establishing a rabbit model of perianal fistulizing Crohn’s disease
Shuang-Shuang Lu, Wen-Jia Liu, Qiu-Ya Niu, Chun-Yan Huo, Yu-Qing Cheng, En-Jing Wang, Rong-Nan Li, Fang-Fang Feng, Yi-Ming Cheng, Rong Liu, Jin Huang
World Journal of Gastroenterology.2022; 28(15): 1536. CrossRef - Modern surgical strategies for perianal Crohn's disease
Gilmara Pandolfo Zabot, Ornella Cassol, Rogerio Saad-Hossne, Willem Bemelman
World Journal of Gastroenterology.2020; 26(42): 6572. CrossRef - Increased prevalence of anti‐TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood
James J. Ashton, Florina Borca, Enrico Mossotto, Tracy Coelho, Akshay Batra, Nadeem A. Afzal, Hang T. T. Phan, Michael Stanton, Sarah Ennis, Robert Mark Beattie
Alimentary Pharmacology & Therapeutics.2019; 49(4): 398. CrossRef - Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn’s Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study
Roy Frei, Nicolas Fournier, Jonas Zeitz, Michael Scharl, Bernhard Morell, Thomas Greuter, Philipp Schreiner, Benjamin Misselwitz, Ekaterina Safroneeva, Alain M Schoepfer, Stephan R Vavricka, Gerhard Rogler, Luc Biedermann
Journal of Crohn's and Colitis.2019; 13(10): 1292. CrossRef - Are Surgical Rates Decreasing in the Biological Era In IBD?
Francesca Di Candido, Gionata Fiorino, Marco Spadaccini, Silvio Danese, Antonino Spinelli
Current Drug Targets.2019; 20(13): 1356. CrossRef
- Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America
- 7,097 View
- 59 Download
- 8 Web of Science
- 7 Crossref
- Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease
- Daniéla Oliveira Magro, Paulo Gustavo Kotze, Carlos Augusto Real Martinez, Michel Gardere Camargo, Dioze Guadagnini, Antonio Ramos Calixto, Ana Carolina Junqueira Vasques, Maria de Lourdes Setsuko Ayrizono, Bruno Geloneze, José Carlos Pareja, Mario José Saad, Claudio Saddy Rodrigues Coy
- Intest Res 2017;15(3):352-357. Published online June 12, 2017
- DOI: https://doi.org/10.5217/ir.2017.15.3.352
-
Abstract
PDFPubReaderePub
<b>Background/Aims</b><br/> Lipopolysaccharide (LPS) is a molecule formed by lipids and polysaccharides and is the major cell wall component of gram-negative bacteria. High LPS levels are known to block CD26 expression by activating Toll-like receptor 4. The aim of this study was to correlate the serum levels of LPS and CD26 in Crohn's disease (CD) patients with serum levels of C-reactive protein (CRP), interleukins, CD activity index, and tumor necrosis factor-α (TNF-α).
Methods Serum samples were collected from 27 individuals (10 with active CD, 10 with inactive CD, and 7 controls) and the levels of LPS, CD26, TNF-α, interleukin-1β (IL-1β), IL-6, IL-17, and CRP were determined by enzyme-linked immunosorbent assay. The levels of LPS and CD26 were then tested for correlation with TNF-α, IL-1β, IL-6, IL-17, and CRP.
Results Serum levels of LPS were significantly elevated in the active CD group (
P =0.003). Levels of IL-1β (P =0.002), IL-6 (P =0.003), and IL-17 (P <0.001) were lower in the CD groups. Serum TNF-α levels were increased in the active CD group. The CRP levels were elevated in the CD groups when compared to controls (P <0.001). The CD26 levels were lower in the CD groups than in the control group (P <0.001). Among the variables analyzed, there was a correlation between LPS and CRP (r=−0.53,P =0.016) in the CD groups.Conclusions Individuals with CD exhibited higher serum levels of LPS varying from a 2- to 6-fold increase depending on disease activity, when compared with healthy controls. CD26 levels were lower in the CD groups. Both LPS and CD26 correlated with disease severity and serve as potential CD biomarkers.
-
Citations
Citations to this article as recorded by- ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Ondřej Kučerka, Martin Malý, Petra Mináriková, Jan M. Horáček
Military Medical Science Letters.2025; 94(1): 27. CrossRef - Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
Kashif Rahim, Muhammad Shan, Ihtisham Ul Haq, Muhammad Nawaz, Sajida Maryam, Mansour Alturki, Abdulaziz Al Khzem, Kamel Metwally, Simona Cavalu, Saleh Alqifari, Galal Yahya
Journal of Inflammation Research.2024; Volume 17: 1897. CrossRef - Interaction between diet and genetics in patients with inflammatory bowel disease
Daniéla Oliveira Magro, Ligia Yukie Sassaki, Júlio Maria Fonseca Chebli
World Journal of Gastroenterology.2024; 30(12): 1644. CrossRef - Quantitative urinary proteome analysis reveals potential biomarkers for disease activity of Behcet’s disease uveitis
Weiwei Qin, Anyi Liang, Xiaoxu Han, Meifen Zhang, Youhe Gao, Chan Zhao
BMC Ophthalmology.2024;[Epub] CrossRef - Dietary fat induced chylomicron-mediated LPS translocation in a bicameral Caco-2cell model
Monic M. M. Tomassen, Coen Govers, A. Paul Vos, Nicole J. W. de Wit
Lipids in Health and Disease.2023;[Epub] CrossRef - Endothelial Glycocalyx Preservation—Impact of Nutrition and Lifestyle
Paula Franceković, Lasse Gliemann
Nutrients.2023; 15(11): 2573. CrossRef - Toll-like Receptors and Cytokine Modulation by Goat Milk Extracellular Vesicles in a Model of Intestinal Inflammation
Chiara Grazia De Ciucis, Floriana Fruscione, Livia De Paolis, Samanta Mecocci, Susanna Zinellu, Lisa Guardone, Giulia Franzoni, Katia Cappelli, Elisabetta Razzuoli
International Journal of Molecular Sciences.2023; 24(13): 11096. CrossRef - Longitudinal flux balance analyses of a patient with episodic colonic inflammation reveals microbiome metabolic dynamics
Arianna Basile, Almut Heinken, Johannes Hertel, Larry Smarr, Weizhong Li, Laura Treu, Giorgio Valle, Stefano Campanaro, Ines Thiele
Gut Microbes.2023;[Epub] CrossRef - Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice
Rachele Gore, Mitra Mohsenipour, Jennifer L. Wood, Gayathri K. Balasuriya, Elisa L. Hill-Yardin, Ashley E. Franks, Manuela Raffatellu
Infection and Immunity.2023;[Epub] CrossRef - MEFV and NLRP3 Inflammasome Expression Is Attributed to Immature Macrophages and Correlates with Serum Inflammatory Proteins in Crohn´s Disease Patients
Frida Gorreja, Charles Caër, Stephen T. A. Rush, Sophia K. Forsskål, Anetta Härtlova, Maria K. Magnusson, Elinor Bexe Lindskog, Lars G. Börjesson, Mattias Block, Mary Jo Wick
Inflammation.2022; 45(4): 1631. CrossRef - Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
Jie Huang, Xinxin Liu, Yingying Wei, Xinlu Li, Shupei Gao, Lingli Dong, Xiaoquan Rao, Jixin Zhong
Frontiers in Immunology.2022;[Epub] CrossRef - Genetic Deletion of LRP5 and LRP6 in Macrophages Exacerbates Colitis-Associated Systemic Inflammation and Kidney Injury in Response to Intestinal Commensal Microbiota
Indumathi Manoharan, Daniel Swafford, Arulkumaran Shanmugam, Nikhil Patel, Puttur D Prasad, Riyaz Mohamed, Qingqing Wei, Zheng Dong, Muthusamy Thangaraju, Santhakumar Manicassamy
The Journal of Immunology.2022; 209(2): 368. CrossRef - The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review
Francisco Jorge Melo, Pedro Pinto-Lopes, Maria Manuela Estevinho, Fernando Magro
Inflammatory Bowel Diseases.2021; 27(7): 1153. CrossRef - Effects of Anthocyanin on Intestinal Health: A Systematic Review
Thaísa Agrizzi Verediano, Hércia Stampini Duarte Martino, Maria Cristina Dias Paes, Elad Tako
Nutrients.2021; 13(4): 1331. CrossRef - Anti-inflammatory activity of Jasminum grandiflorum L. subsp. floribundum (Oleaceae) in inflammatory bowel disease and arthritis models
Riham A. El-Shiekh, Dorria Hussein, Attia H. Atta, Samar M. Mounier, Mohamed R. Mousa, Essam Abdel-Sattar
Biomedicine & Pharmacotherapy.2021; 140: 111770. CrossRef - Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management
Jasmijn A. M. Sleutjes, Jeanine E. Roeters van Lennep, C. Janneke van der Woude, Annemarie C. de Vries
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef - Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease
Sabrina A Fernandes, Carina Rossoni, Vivian W Koch, Marcello Imbrizi, Rosana Evangelista-Poderoso, Letícia Pereira Pinto, Daniéla Oliveira Magro
Artificial Intelligence in Gastroenterology.2021; 2(4): 111. CrossRef - Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Sera Positive for ASCA and ANCA
Aristo Vojdani, Elroy Vojdani, Martha Herbert, Datis Kharrazian
International Journal of Molecular Sciences.2020; 21(4): 1381. CrossRef - CD26/DPP4 - a potential biomarker and target for cancer therapy
Njanja Enz, Gwendolyn Vliegen, Ingrid De Meester, Wolfgang Jungraithmayr
Pharmacology & Therapeutics.2019; 198: 135. CrossRef - Is there a possible correlation between antibodies against lipopolysaccharide, intestinal and blood-brain barrier proteins in IBD subjects?
Aristo Vojdani
Autoimmunity Reviews.2019; 18(6): 639. CrossRef - CD26 in autoimmune diseases: The other side of “moonlight protein”
Yunjuan Zhao
International Immunopharmacology.2019; 75: 105757. CrossRef - Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production
Daniéla Oliveira Magro, Andrey Santos, Dioze Guadagnini, Flavia Moreira de Godoy, Sylvia Helena Monteiro Silva, Wilson José Fernandes Lemos, Nicola Vitulo, Sandra Torriani, Lilian Vital Pinheiro, Carlos Augusto Real Martinez, Mario José Abdalla Saad, Clau
Scientific Reports.2019;[Epub] CrossRef - Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults
Tiansheng Wang, Jeff Y. Yang, John B. Buse, Virginia Pate, Huilin Tang, Edward L. Barnes, Robert S. Sandler, Til Stürmer
Diabetes Care.2019; 42(11): 2065. CrossRef - Emerging concepts in non-invasive monitoring of Crohn’s disease
Wojciech Marlicz, Karolina Skonieczna-Żydecka, Konstantinos John Dabos, Igor Łoniewski, Anastasios Koulaouzidis
Therapeutic Advances in Gastroenterology.2018;[Epub] CrossRef - VISCERAL FAT IS INCREASED IN INDIVIDUALS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS WITH HEALTHY CONTROLS
Daniéla Oliveira MAGRO, Maria Rita Lazzarini BARRETO, Everton CAZZO, Michel Gardere CAMARGO, Paulo Gustavo KOTZE, Claudio Saddy Rodrigues COY
Arquivos de Gastroenterologia.2018; 55(2): 142. CrossRef
- ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
- 8,849 View
- 59 Download
- 24 Web of Science
- 25 Crossref
First
Prev
